<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525733</url>
  </required_header>
  <id_info>
    <org_study_id>MMA-0610-0607</org_study_id>
    <nct_id>NCT00525733</nct_id>
  </id_info>
  <brief_title>Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)</brief_title>
  <official_title>A Phase II, Randomized Trial of Open-Label Truvada With Darunavir/Ritonavir Versus Multiclass Therapy With Truvada, Darunavir/Ritonavir, Maraviroc and Raltegravir in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aaron Diamond AIDS Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers are involved in a phase II, randomized, two-arm study, comparing the
      efficacy, safety, and tolerability of open-label ritonavir (RTV)-enhanced darunavir with
      Truvada to a 5-drug multi-class regimen including truvada, darunavir/ritonavir/maraviroc/and
      raltegravir on acutely HIV-1-infected, antiretroviral (ARV) drug-naïve men and women.
      Subjects will participate for at least 60 weeks and up to 96 weeks if in the opinion of the
      investigator and patient that continued therapy is in the patient's best interest.

      Hypotheses:

        -  Multi-class antiretroviral therapy (ART) is superior to RTV-enhanced ATV in combination
           with Emtricitabine/Tenofovir DF (FTC/TDF) with respect to suppression of viral
           replication.

        -  Multi-class ART is superior to RTV-enhanced ATV in combination with FTC/TDF with respect
           to immune reconstitution in peripheral blood and in the gastrointestinal mucosa.

        -  Multi-class ART is equivalent to RTV-enhanced ATV in combination with FTC/TDF with
           respect to tolerability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  DURATION: Subjects will participate for at least 60 weeks and up to 96 weeks if in the
           opinion of the investigator and patient that continued therapy is in the patient's best
           interest.

        -  SAMPLE SIZE: 36 subjects randomized 2:1 multi-class versus standard antiretroviral
           therapy.

        -  POPULATION: Acutely HIV-1-infected, antiretroviral (ARV) drug-naïve (≤ 7 days of ARV
           treatment at anytime prior to study entry*) men and women ≥ 18 years of age.

        -  REGIMEN: At entry subjects will be randomized to one of the following in a 1:2 ratio:

      ARM A: FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ritonavir 100 mg QD

      ARM B: FTC 200 mg/TDF 300 mg QD + darunavir 800mg/ritonavir 100 mg QD + Raltegravir 400 mg
      BID + Maraviroc 150 mg BID

      The three primary objectives are:

        1. To assess whether a multi-class regimen could completely suppress virus replication in
           HIV infected individuals based on:

             -  Plasma HIV-1 RNA levels at 48 weeks

             -  Ultrasensitive &lt; 50 copy assay

             -  5 copy assay

             -  1 copy assay

             -  Cell associated HIV-1RNA levels at week 48

             -  Proviral DNA

             -  Levels at week 48

             -  Decay rates from week 12 to week 48

        2. To determine whether multi-class antiviral therapy results in enhanced immune
           reconstitution in peripheral blood and gastrointestinal mucosa based on flow and
           immunohistochemistry.

        3. To assess tolerability of multi-class compact antiviral therapy to that of standard
           compact antiviral therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome of This Study is the Proportion of Patients Having Detectable HIV-1 RNA Using the Single Copy Assay After 48 Weeks of Treatment and the Study Hypothesis is That New Treatment is Better Than the Control Group.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>3-drug standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ +ritonavir 100 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-drug experimental therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FTC 200 mg/TDF 300 mg QD + darunavir 800 mg + ritonavir 100 mg QD + Raltegravir 400 mg BID + Maraviroc 150 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darunavir 800 mg</intervention_name>
    <description>darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)</description>
    <arm_group_label>3-drug standard therapy</arm_group_label>
    <arm_group_label>5-drug experimental therapy</arm_group_label>
    <other_name>prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC 200 mg/TDF 300mg</intervention_name>
    <description>Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)</description>
    <arm_group_label>3-drug standard therapy</arm_group_label>
    <arm_group_label>5-drug experimental therapy</arm_group_label>
    <other_name>FTC/TDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)</description>
    <arm_group_label>5-drug experimental therapy</arm_group_label>
    <other_name>selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)</description>
    <arm_group_label>5-drug experimental therapy</arm_group_label>
    <other_name>isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir 100 mg</intervention_name>
    <description>one tablet of ritonavir is taken with darunavir daily</description>
    <arm_group_label>3-drug standard therapy</arm_group_label>
    <arm_group_label>5-drug experimental therapy</arm_group_label>
    <other_name>norvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute HIV-1 infection defined as:

               -  Negative ELISA/Western Blot or indeterminate Western Blot in the presence of
                  HIV-1 RNA &gt; 5,000 copies/ml.

               -  Positive HIV-1 serology with a detuned ELISA O.D. value below 0.5.

               -  A documented negative serology within 180 days of screening and a positive HIV-1
                  serology at screening

          -  Antiretroviral (ARV) drug-naïve (defined as ≤ 7 days of ARV treatment at any time
             prior to entry*).

          -  The only exceptions are:

               -  Use of antivirals as part of post-exposure prophylaxis (PEP) provided the subject
                  did not acquire HIV-1 infection from the event that required PEP.

               -  Therapy with an investigational ARV drug that was not an NRTI, NNRTI, or PI.

          -  Laboratory values obtained within 30 days prior to study entry.

               -  Absolute neutrophil count (ANC) ≥ 500/mm3

               -  Hemoglobin ≥ 8.0 g/dL

               -  Platelet count ≥ 40,000/mm3

               -  AST (SGOT), ALT (SGPT), and alkaline phosphatase ≤ 7.5 × ULN

               -  Total bilirubin ≤2.5 x ULN

               -  Calculated creatinine clearance ≥60 mL/min as estimated by the Cockcroft-

        Gault equation:

        For men, (140 - age in years) x (body weight in kg) ÷ (serum creatinine in mg/dL x 72) =
        CrCl (mL/min)*

          -  For women, multiply the result by 0.85 = CrCl (mL/min) NOTE: A program to assist in
             calculations is available on the DMC web site at: http://www.fstrf.org/ACTG/ccc.html

          -  For women of reproductive potential, negative serum or urine pregnancy test within 48
             hours prior to initiating study medications unless otherwise specified by product
             labeling.

          -  Female candidates of reproductive potential is defined as girls who have reached
             menarche or women who have not been post-menopausal for at least 24 consecutive months
             (i.e., who have had menses within the preceding 24 months) or have not undergone
             surgical sterilization (e.g., hysterectomy, or bilateral oophorectomy, or bilateral
             tubal ligation).

        Contraception requirements:

          -  Female candidates of reproductive potential, who are participating in sexual activity
             that could lead to pregnancy, must agree that they will use at least one reliable
             method of contraception while receiving the protocol-specified drugs and for 6 weeks
             after stopping the medications.

        Male Candidates:

          -  If you are a heterosexual male, you and your sexual partner must agree to use
             acceptable methods of birth control during the entire study.

          -  Acceptable methods of birth control include intrauterine device (IUD), diaphragm with
             spermicide, condoms or not having sex.

          -  Oral contraceptives alone are not an acceptablemethod of birth control.

          -  Men and women age ≥ 18 years.

          -  Ability and willingness of subject to give written informed consent.

        Exclusion Criteria:

          -  Currently breast-feeding.

          -  Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), systemic
             cytotoxic chemotherapy, or investigational therapy within 30 days prior to study
             entry. NOTE: Subjects receiving stable physiologic glucocorticoid doses, defined as
             prednisone ≤ 10 mg/day, will not be excluded.

          -  Known allergy/sensitivity to study drugs or their formulations.

          -  Active drug or alcohol use or dependence that, in the opinion of the site
             investigator, would interfere with adherence to study requirements.

          -  Serious illness requiring systemic treatment and/or hospitalization until candidate
             either completes therapy or is clinically stable on therapy, in the opinion of the
             site investigator, for at least 7 days prior to study entry.

        NOTE: Oral candidiasis, vaginal candidiasis, mucocutaneous herpes simplex, and other minor
        illnesses (as judged by the site investigator) have no restriction.

          -  Clinically relevant cardiac conduction system disease. This includes severe first
             degree atrioventricular block (PR interval &gt; 0.26 seconds), or second, or third-degree
             atrioventricular block.

          -  Requirement for any current medications that are prohibited with any study treatment.

          -  Evidence of major resistance-associated mutations on genotype performed within 14 days
             of day 1. Major resistance-associated mutations include: NRTI: K65R or inserts Q151M,
             M184V/I, PI: I50L/V, I84V, N88S.

          -  Viral population that is either dual tropic or X4 tropic using the Monogram assay
             (patients will be entered and be treated pending this result performed within 28 days
             of day 1).

          -  Current imprisonment or involuntary incarceration in a medical facility for
             psychiatric or physical (e.g., infectious disease) illness.

          -  Participation in any other clinical trial within 30 days prior to screening.

          -  Any other clinical conditions or prior therapy that, in the opinion of the
             investigator, would make the subject unsuitable for the study or unable to comply with
             the requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Markowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rucares.org/clinicalstudies/list.php?searchTerm=&amp;x=20&amp;y=12&amp;pi_id=29</url>
    <description>The Rockefeller University Hospital</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2007</study_first_submitted>
  <study_first_submitted_qc>September 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2007</study_first_posted>
  <results_first_submitted>January 21, 2015</results_first_submitted>
  <results_first_submitted_qc>February 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2015</results_first_posted>
  <last_update_submitted>February 24, 2015</last_update_submitted>
  <last_update_submitted_qc>February 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>Acute Infection</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>3-drug Standard Therapy</title>
          <description>FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ritonavir 100 mg QD
darunavir: Darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
Emtricitabine/tenofovir DF: Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)</description>
        </group>
        <group group_id="P2">
          <title>5-drug Experimental Therapy</title>
          <description>FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ritonavir 100 mg QD + Raltegravir 400 mg BID + Maraviroc 150 mg BID
darunavir: Darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
Emtricitabine/tenofovir DF: Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
Maraviroc: Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)
Raltegravir: Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is an as treated analysis. Baseline characteristics describe subjects available for primary endpoint analysis at week 48. There were 34 subjects available for primary endpoint analysis however 2 subjects were not able to be analyzed due to primer mismatch therefore results are available for 32 subjects in the primary endpoint analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>3-drug Standard Therapy</title>
          <description>FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ritonavir 100 mg QD
darunavir: Darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
Emtricitabine/tenofovir DF: Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)</description>
        </group>
        <group group_id="B2">
          <title>5-drug Experimental Therapy</title>
          <description>FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ritonavir 100 mg QD + Raltegravir 400 mg BID + Maraviroc 150 mg BID
darunavir: Darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
Emtricitabine/tenofovir DF: Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
Maraviroc: Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)
Raltegravir: Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" lower_limit="25" upper_limit="48"/>
                    <measurement group_id="B2" value="41" lower_limit="29" upper_limit="69"/>
                    <measurement group_id="B3" value="38" lower_limit="25" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean log baseline HIV-1 RNA</title>
          <units>log copies/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" lower_limit="3.1" upper_limit="6.4"/>
                    <measurement group_id="B2" value="6.3" lower_limit="4.8" upper_limit="7.0"/>
                    <measurement group_id="B3" value="5.8" lower_limit="3.1" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean CD4+ T-cell count</title>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="539" lower_limit="230" upper_limit="1066"/>
                    <measurement group_id="B2" value="405" lower_limit="305" upper_limit="524"/>
                    <measurement group_id="B3" value="496" lower_limit="230" upper_limit="1066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome of This Study is the Proportion of Patients Having Detectable HIV-1 RNA Using the Single Copy Assay After 48 Weeks of Treatment and the Study Hypothesis is That New Treatment is Better Than the Control Group.</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3-drug Standard Therapy</title>
            <description>FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ritonavir 100 mg QD
darunavir: Darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
Emtricitabine/tenofovir DF: Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)</description>
          </group>
          <group group_id="O2">
            <title>5-drug Experimental Therapy</title>
            <description>FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ritonavir 100 mg QD + Raltegravir 400 mg BID + Maraviroc 150 mg BID
darunavir: Darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
Emtricitabine/tenofovir DF: Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
Maraviroc: Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)
Raltegravir: Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome of This Study is the Proportion of Patients Having Detectable HIV-1 RNA Using the Single Copy Assay After 48 Weeks of Treatment and the Study Hypothesis is That New Treatment is Better Than the Control Group.</title>
          <units># subjects without detectable viremia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>3-drug Standard Therapy</title>
          <description>FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ritonavir 100 mg QD
darunavir: Darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
Emtricitabine/tenofovir DF: Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)</description>
        </group>
        <group group_id="E2">
          <title>5-drug Experimental Therapy</title>
          <description>FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ritonavir 100 mg QD + Raltegravir 400 mg BID + Maraviroc 150 mg BID
darunavir: Darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
Emtricitabine/tenofovir DF: Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
Maraviroc: Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)
Raltegravir: Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Martin Markowitz MD</name_or_title>
      <organization>Aaron Diamond AIDS Research Center</organization>
      <phone>212-448-5020</phone>
      <email>mmarkowitz@adarc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

